MedPath

E-2814

Generic Name
E-2814
Clinical Trials
Related News

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Phase 2
Recruiting
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-04-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
90
Registration Number
NCT06602258
Locations
🇺🇸

Advanced Memory Research Institute, Toms River, New Jersey, United States

🇺🇸

Banner Sun Health Research Institute, Sun City, Arizona, United States

🇺🇸

Sharp Neurocognitive Research Center at Sharp Mesa Vista Hospital, San Diego, California, United States

and more 31 locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Phase 2
Active, not recruiting
Conditions
Alzheimers Disease
Dementia
Alzheimers Disease, Familial
Interventions
Drug: Matching Placebo (E2814)
First Posted Date
2022-03-08
Last Posted Date
2025-04-03
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
197
Registration Number
NCT05269394
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

USC Keck School of Medicine, Los Angeles, California, United States

🇨🇴

Grupo de Neurociencias Sede de la Universidad de Antioquia, Medellín, Colombia

and more 35 locations

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer Disease
Interventions
First Posted Date
2021-07-21
Last Posted Date
2024-12-27
Lead Sponsor
Eisai Inc.
Target Recruit Count
8
Registration Number
NCT04971733
Locations
🇺🇸

UC San Diego Altman Clinical and Translational Research Insititute Clinic, La Jolla, California, United States

🇬🇧

National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust, London, United Kingdom

🇺🇸

Indiana University School of Medicine, Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: E2814-matched placebo
First Posted Date
2020-01-18
Last Posted Date
2023-04-06
Lead Sponsor
Eisai Inc.
Target Recruit Count
72
Registration Number
NCT04231513
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

🇺🇸

California Clinical Trials Medical Group/Parexel International, Glendale, California, United States

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Phase 2
Recruiting
Conditions
Alzheimers Disease
Dementia
Alzheimers Disease, Familial
Interventions
Drug: Matching Placebo (Gantenerumab)
Drug: Matching Placebo (Solanezumab)
Drug: Matching Placebo (E2814)
First Posted Date
2013-01-03
Last Posted Date
2025-04-03
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
490
Registration Number
NCT01760005
Locations
🇨🇦

UBC Hospital, Vancouver, British Columbia, Canada

🇺🇸

University of Washington, Seattle, Washington, United States

🇫🇷

CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy